Yogic Breathing and IBS

Sponsor
Texas State University (Other)
Overall Status
Completed
CT.gov ID
NCT04225104
Collaborator
(none)
14
1
2
10.5
1.3

Study Details

Study Description

Brief Summary

Adults with irritable bowel syndrome (IBS) are being randomized to a yogic breathing or control condition. Participants randomized to the yogic breathing group will be asked to complete a 2-minute yogic breathing video 5 to 7 days per week at home for 4 weeks and control group participants will be asked to maintain their current activities. Participants in this group will be given access to the yogic breathing video at the end of the 4-week control period. IBS symptoms and autonomic and vascular function will be assessed at baseline and at the end of week 4 in both groups.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Yogic breathing intervention
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
14 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Masking Description:
Members of the investigative team will be blinded to the participant's group assignment until all testing is completed.
Primary Purpose:
Treatment
Official Title:
Effects of Yogic Breathing on Microvascular Endothelial Function and Symptoms in Participants With IBS
Actual Study Start Date :
Apr 15, 2019
Actual Primary Completion Date :
Feb 1, 2020
Actual Study Completion Date :
Mar 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Yogic breathing intervention

Participants assigned to this group will complete a 20-minute yogic breathing video at least 5 days per week for 4 weeks. All sessions except the initial yogic breathing session will be completed at home. Participants will complete the first session at Texas State under the supervision of the investigative team for familiarization.

Behavioral: Yogic breathing intervention
Yogic breathing will be completed while following a video provided by the investigative team. Breathing practices consist of slow, deep, relaxation breathing and are led by a certified yoga instructor.

No Intervention: Control

Participants in the control group will be asked to maintain their current daily activities and will be given access to the yogic breathing video once all follow-up testing has been completed at the end of week 4.

Outcome Measures

Primary Outcome Measures

  1. IBS Symptoms [Once at baseline]

    IBS-Symptom Severity Scale will be administered.

  2. IBS Symptoms [Once at the end of week 2]

    IBS-Symptom Severity Scale will be administered.

  3. IBS Symptoms [Once at the end of week 4]

    IBS-Symptom Severity Scale will be administered.

  4. Autonomic function [Once at baseline]

    Heart rate variability will be assessed.

  5. Autonomic function [Once at the end of week 2]

    Heart rate variability will be assessed.

  6. Autonomic function [Once at the end of week 4]

    Heart rate variability will be assessed.

  7. Autonomic function [Once at baseline]

    Exercise heart rate recovery will be measured.

  8. Autonomic function [Once at the end of week 2]

    Exercise heart rate recovery will be measured.

  9. Autonomic function [Once at the end of week 4]

    Exercise heart rate recovery will be measured.

  10. Microvascular function [Once at baseline]

    Laser Doppler flowmetry at baseline and in response to local heating will be measured.

  11. Microvascular function [Once at the end of week 4]

    Laser Doppler flowmetry and in response to local heating will be measured.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Must have a formal diagnosis of IBS and not be enrolled in any other clinical trials.
Exclusion Criteria:
    1. current, regular practice of yogic breathing at least 5 minutes per day and 2) chronic obstructive pulmonary disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stacy Hunter San Marcos Texas United States 78666

Sponsors and Collaborators

  • Texas State University

Investigators

  • Principal Investigator: Stacy D Hunter, PhD, Texas State University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Texas State University
ClinicalTrials.gov Identifier:
NCT04225104
Other Study ID Numbers:
  • 6275
First Posted:
Jan 13, 2020
Last Update Posted:
Aug 6, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 6, 2021